| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was
selected by an in-house editor and fully peer-reviewed by external
reviewers. It is distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this
work non-commercially, and license their derivative works on
different terms, provided the original work is properly cited and
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing
Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ayato Murata, Takuya Genda, Takafumi Ichida, Nozomi Amano, Sho Sato, Hironori Tsuzura, Shunsuke Sato, Yutaka Narita, Yoshio Kanemitsu, Yuji Shimada, Katsuharu Hirano, Katsuyori Iijima, Ryo Wada, Akihito Nagahara and Sumio Watanabe |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan |
|
|
| Corresponding Author |
Takuya Genda, MD, PhD, Associate Professor, Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, 1129 Nagaoka, Izunokuni-shi, Shizuoka 410-2295, Japan. genda@rice.ocn.ne.jp |
| Key Words |
Human AKR1B10 protein; Hepatocellular carcinoma; Chronic hepatitis C; Immunohistochemistry; Risk factor; Sustained virological response |
| Core Tip |
Expression of a cancer-related oxidoreductase, aldo-keto reductase family 1 member B10 (AKR1B10) was upregulated in the liver in patients with chronic hepatitis C (CHC). High AKR1B10 expression was associated in a statistically significant manner with the risk of hepatocellular carcinoma (HCC) development even after sustained virological response (SVR) was achieved through interferon-based antiviral therapy. Pretreatment AKR1B10 expression of 8% was associated with a > 15-fold-increased risk of HCC development. Thus, AKR1B10 is not only a cancer biomarker but also a novel predictive marker for assessing the risk of HCC development in CHC patients who achieved SVR. |
| Publish Date |
2016-09-04 14:49 |
| Citation |
Murata A, Genda T, Ichida T, Amano N, Sato S, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Shimada Y, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol 2016; 22(33): 7569-7578 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i33/7569.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i33.7569 |
